IRIS
BERTOLI, ADA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.054
EU - Europa 2.372
AS - Asia 1.143
SA - Sud America 29
AF - Africa 12
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 8
Totale 25.628
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.048
SG - Singapore 554
IT - Italia 377
DE - Germania 347
SE - Svezia 315
CN - Cina 286
UA - Ucraina 285
PL - Polonia 234
KR - Corea 223
IE - Irlanda 221
FR - Francia 185
RU - Federazione Russa 157
GB - Regno Unito 111
FI - Finlandia 72
CZ - Repubblica Ceca 20
NL - Olanda 16
BE - Belgio 14
BR - Brasile 14
HK - Hong Kong 13
JP - Giappone 12
VN - Vietnam 12
AU - Australia 9
CH - Svizzera 8
CL - Cile 8
IN - India 7
KG - Kirghizistan 7
PK - Pakistan 7
EU - Europa 6
CA - Canada 5
ET - Etiopia 5
AR - Argentina 4
BD - Bangladesh 4
TR - Turchia 4
CO - Colombia 3
ES - Italia 3
UZ - Uzbekistan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AT - Austria 2
DK - Danimarca 2
MN - Mongolia 2
TW - Taiwan 2
ZA - Sudafrica 2
AL - Albania 1
CM - Camerun 1
EE - Estonia 1
EG - Egitto 1
IL - Israele 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MX - Messico 1
NG - Nigeria 1
NP - Nepal 1
NZ - Nuova Zelanda 1
QA - Qatar 1
RO - Romania 1
SA - Arabia Saudita 1
SC - Seychelles 1
TH - Thailandia 1
TN - Tunisia 1
Totale 25.628
Salva come PNG Salva come JPEG
Città #
Woodbridge 6.679
Wilmington 6.056
Houston 4.703
Fairfield 714
Chandler 589
Ann Arbor 528
Singapore 474
Ashburn 302
Seattle 300
Jacksonville 242
Kraków 231
Cambridge 228
Dublin 206
Rome 190
Medford 156
Santa Clara 115
Dearborn 112
Beijing 103
New York 103
Zhengzhou 75
Lawrence 73
San Diego 52
Milan 45
Menlo Park 36
Mülheim 35
Moscow 34
Palo Alto 25
Creede 20
Boardman 18
San Francisco 18
Colorado Springs 17
Munich 17
Falls Church 16
University Park 15
Nanjing 14
Olomouc 14
Brussels 13
London 13
Phoenix 12
Shanghai 12
Norwalk 11
Bari 10
Guangzhou 10
Helsinki 10
Dong Ket 9
Hong Kong 9
Redwood City 8
Verona 8
Hefei 7
Jinan 7
Los Angeles 7
Mountain View 7
Amsterdam 6
Brno 6
Kunming 6
Magenta 6
Cedarhurst 5
Coventry 5
Manitou Springs 5
Nanchang 5
Palermo 5
Saint Petersburg 5
Seoul 5
Fuzhou 4
Hangzhou 4
Kilburn 4
Nuremberg 4
Nürnberg 4
San Mateo 4
Adelaide 3
Bogotá 3
Detroit 3
Hounslow 3
Indiana 3
Lahore 3
Lappeenranta 3
Lausanne 3
Nanning 3
Naples 3
Novokuznetsk 3
Padova 3
Perugia 3
Redmond 3
St. George 3
São Paulo 3
The Dalles 3
Tokyo 3
Toronto 3
Wuhan 3
Acton 2
Albano Laziale 2
Belgrade 2
Bengaluru 2
Binasco 2
Brescia 2
Buenos Aires 2
Camponogara 2
Center 2
Central 2
Chengdu 2
Totale 22.873
Salva come PNG Salva come JPEG
Nome #
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 512
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 472
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 448
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 446
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso 446
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child 437
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 436
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 435
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 434
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 429
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 429
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 429
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy 426
Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed 426
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 423
Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. 423
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 420
Altered deoxyribonucleotide pools in T-lymphoblastoid cells expressing the multisubstrate nucleoside kinase of Drosophila melanogaster 419
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study 418
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 412
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 412
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 411
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 408
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 403
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment 403
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 398
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure 387
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 386
A case of Italian HIV-2 infection: a genetic analysis 384
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 380
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 379
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 378
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 377
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 374
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 372
The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages 372
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 372
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 370
Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution 369
Temporal change in the use of genotypic resistance testing over the years 1999--2003 367
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels 366
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 366
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 362
Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy 361
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 358
Novel reverse transcriptase mutations specifically associated with selected anti-Hbv treatment can induce alterations and stop-codons in Hbv S antigen 358
null 357
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 356
Overlapping structure of HBV genome and immune selection pressure are critical forces modulating HBV evolution 355
Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia 348
Plasma HIV RNA decline and emergence of drug resistance mutations among patients with multiple virologic failures receiving resistance testing-guided HAART 343
Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus 343
HIV-1 non-B subtypes in Italy: a growing trend 341
Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome 333
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen 333
Total HIV-1 DNA detection and quantification in peripheral blood by COBAS®AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 325
Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy 323
The V118I mutation as a marker of advanced HIV infection and disease progression 322
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 318
The Lowest X4 Geno2Pheno-False Positive Rate Is Associated with Greater CD4-Depletion 313
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection 310
Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000-14 298
Recent transmission clustering of HIV-1 C and CRF17-BF strains characterized by NNRTI-related mutations among newly diagnosed men in central Italy 274
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 268
HIV MDR is still a relevant issue despite its dramatic drop over the years 174
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro 172
Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection 111
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients 92
Long-term SARS-CoV-2 infection associated with viral dissemination in different body fluids Including bile in two patients with acute cholecystitis 92
Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers 83
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment 76
HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation 64
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 61
An HIV Type 2 Case Series in Italy: A Phylogenetic Analysis 54
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice 51
Genotypic HIV-1 tropism determination might help to identify people with exhausted treatment options and advanced disease 47
Infection Rate of Respiratory Viruses in the Pandemic SARS-CoV-2 Period Considering Symptomatic Patients: Two Years of Ongoing Observations 40
Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings 38
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21 32
Genetic heterogenicity of HIV-1 protease in drug-naive and drug-treated HIV-positive patients 29
Evaluation of HIV-1 integrase variability by combining computational and probabilistic approaches 27
Factors predictive of virological response after genotyping resistance test (GRT): data from an unselected cohort 26
Prevalence of HDV infection in Central Italy has remained stable across the last two decades with dominance of sub-genotypes 1 and characterized by elevated viral replication 24
Stable temporal trend of HDV seroprevalence in central Italy across the last two decades with the circulation of HDV sub-genotypes 1 inducing different inflammatory stimuli 23
Factors predictive of multinucleoside analogue-resistance mutations in an unselected cohort of HAART-failed patients. 21
Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies 18
Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals 18
Temporal characterization of frequency of drug-resistance associated mutations in the HIV-1 protease and reverse transcriptase 17
Time to detection and loss of M184 genotypic mutation among HIV patients treated with 3TC and failing an HAART regimen 16
Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings 15
Prevalence and phenotypic susceptibility to doravirine of the HIV-1 reverse transcriptase V106I polymorphism in B and non-B subtypes 14
Cross-resistance among NNRTIs: evaluation of the option of recycling Efavirenz after Nevirapine failure 14
Identification of the Minimal Conserved Structure of the HIV-Reverse Transcriptase under the Presence and Absence of Drug Pressure 13
Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation 12
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 8
Totale 25.935
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.140
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.140
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.234 0 0 0 0 544 705 589 537 544 523 381 411
2020/20213.739 404 430 439 477 340 413 544 350 80 77 128 57
2021/20221.111 59 77 106 65 33 88 46 40 207 81 44 265
2022/20231.445 119 136 113 186 104 288 87 138 117 47 76 34
2023/2024449 57 10 30 20 48 101 25 21 10 20 6 101
2024/20251.060 93 507 244 118 98 0 0 0 0 0 0 0
Totale 25.935